Eduardo Fernandez-Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eduardo Fernandez-Cruz has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Javier Carbone
Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
3 shared publications Joaquín Navarro
Clinical Immunology Division, Hospital General Universitario Gregorio Marañón, Microbiology Department, Universidad Complutense de Madrid, Madrid, Spain
2 shared publications- Juana Gil
Servicio de Inmunología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2 shared publications Aina Arbós
1 shared publication- Antoni Gayà
Cell Therapy and Tissue Engineering Group, Research Institute on Health Sciences (IUNICS), University of the Balearic Islands, Palma, Spain
1 shared publication Antonio Gallego
1 shared publication
Latest Publications
- 11 February 2012
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 4 (3) , e335-e343
Active fraction from Ganoderma lucidum with apoptosis activity on peripheral blood mononuclear cells from chronic lymphocytic leukemia
- 11 February 2012
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 4 (3) , e335-e343
Active fraction from Ganoderma lucidum with apoptosis activity on peripheral blood mononuclear cells from chronic lymphocytic leukemia
- 31 July 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48 (3) , 168-172
Prognostic value of peripheral blood mononuclear cell-associated HIV-1 DNA for virological outcome in asymptomatic HIV-1 chronic infection
- 31 July 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48 (3) , 168-172
Prognostic value of peripheral blood mononuclear cell-associated HIV-1 DNA for virological outcome in asymptomatic HIV-1 chronic infection
- 30 June 2009
- Published by Elsevier in International Immunopharmacology
- Vol. 9 (6) , 649-652
Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation
- 30 June 2009
- Published by Elsevier in International Immunopharmacology
- Vol. 9 (6) , 649-652
Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation
- 23 August 2007
- Vol. 27 (2) , 191-3
[Chronic angioedema and blastocystis hominis infection].
The presence of urticaria associated with Blastocystic Hominis infection has been described in very few studies. To the best of our knowledge, no cases of chronic angioedema associated with Blastocystic hominis have been published. The clinical and immunological data of a patient with said association is presented. In the last 5 years, a 21 year old woman suffered episodic spells of angioedema which affected her lips, face and upper limbs accompanied by recurring urticaria. The patient continually used antihistamines and corticoids. Laboratory and immunological tests were normal. Blastocystic hominis in faeces was identified on three occasions. The angioedema and urticaria, as well as the intestinal infection, were successfully treated with paramomycin sulphate. The angiodema and urticaria continue in remission after 24 months of followup care. This case helps to encourage studies to establish an association between the infection by Blastocystis hominis and the presence of chronic angioedema which does not respond to standard treatment, as this condition can seriously affect the quality of life of sufferers.
- 23 August 2007
- Vol. 27 (2) , 191-3
[Chronic angioedema and blastocystis hominis infection].
The presence of urticaria associated with Blastocystic Hominis infection has been described in very few studies. To the best of our knowledge, no cases of chronic angioedema associated with Blastocystic hominis have been published. The clinical and immunological data of a patient with said association is presented. In the last 5 years, a 21 year old woman suffered episodic spells of angioedema which affected her lips, face and upper limbs accompanied by recurring urticaria. The patient continually used antihistamines and corticoids. Laboratory and immunological tests were normal. Blastocystic hominis in faeces was identified on three occasions. The angioedema and urticaria, as well as the intestinal infection, were successfully treated with paramomycin sulphate. The angiodema and urticaria continue in remission after 24 months of followup care. This case helps to encourage studies to establish an association between the infection by Blastocystis hominis and the presence of chronic angioedema which does not respond to standard treatment, as this condition can seriously affect the quality of life of sufferers.
- 1 September 2006
- Vol. 91 (9) , 1257-60
Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection.
Perforin gene (PRF1) mutations have been reported in 20-30% of patients with familial hemophagocytic lymphohistiocytosis (FHL), an autosomal recessive disorder of infancy and early childhood that impairs or abolishes lymphocyte cytotoxicity. We report the first case of FHL in an adult patient homozygous for A91V in PRF1 with tuberculosis. The monozygotic twin of the patient is healthy. A91V confers genetic susceptibility for the development of FHL, but is not enough to trigger the disease on its own. We discuss the role of the A91V change together with M. tuberculosis infection as synergistic factors in the late onset of FHL.
- 1 September 2006
- Vol. 91 (9) , 1257-60
Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection.
Perforin gene (PRF1) mutations have been reported in 20-30% of patients with familial hemophagocytic lymphohistiocytosis (FHL), an autosomal recessive disorder of infancy and early childhood that impairs or abolishes lymphocyte cytotoxicity. We report the first case of FHL in an adult patient homozygous for A91V in PRF1 with tuberculosis. The monozygotic twin of the patient is healthy. A91V confers genetic susceptibility for the development of FHL, but is not enough to trigger the disease on its own. We discuss the role of the A91V change together with M. tuberculosis infection as synergistic factors in the late onset of FHL.
- 1 December 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (6) , 739-752
The potential role of the HIV-1 immunogen (Remune®) as a therapeutic vaccine in the treatment of HIV infection
Immune-based therapies, such as therapeutic vaccination, that might preserve, restore, enhance and induce new HIV-specific immunologic responses are currently being explored. HIV-specific immunotherapy with Remune® (The Immune Response Corp.) offers the opportunity to boost immune responses against HIV-1. The clinical trial program in a wide range of subjects has established the efficacy of Remune in stimulating an appropriate immune response in HIV-positive individuals. Furthermore, a recent unblinded study conducted in Europe has documented a significant effect of Remune on viral load. Evidence regarding clinical end points is more difficult to collect. The same studies have revealed no serious safety issues in a total of more than 2000 Remune-treated patients. It is therefore reasonable to suggest that the risk–benefit ratio of Remune could be positive.
- 1 December 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (6) , 739-752
The potential role of the HIV-1 immunogen (Remune®) as a therapeutic vaccine in the treatment of HIV infection
Immune-based therapies, such as therapeutic vaccination, that might preserve, restore, enhance and induce new HIV-specific immunologic responses are currently being explored. HIV-specific immunotherapy with Remune® (The Immune Response Corp.) offers the opportunity to boost immune responses against HIV-1. The clinical trial program in a wide range of subjects has established the efficacy of Remune in stimulating an appropriate immune response in HIV-positive individuals. Furthermore, a recent unblinded study conducted in Europe has documented a significant effect of Remune on viral load. Evidence regarding clinical end points is more difficult to collect. The same studies have revealed no serious safety issues in a total of more than 2000 Remune-treated patients. It is therefore reasonable to suggest that the risk–benefit ratio of Remune could be positive.